| Health / Medical Topics |
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation. (NCI Thesaurus)
YOU MAY ALSO LIKE
A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein hormone human chorionic gonadotropin (HCG). HCG…
An immunoconjugate of recombinant CD4 antigen (rCD4) covalently linked to an immunoglobulin G heavy chain with activity against human immunodeficiency virus…
A recombinant human IgG4 monoclonal antibody directed against transforming growth factor-beta (TGFb) with potential antineoplastic activity. Recombinant human anti-TGF-beta monoclonal antibody specifically…
A recombinant, soluble glycosylated form of human angiotensin converting enzyme 2 (rhACE2) with antihypertensive and potential antineoplastic activities. Recombinant human angiotensin converting…
A long-acting recombinant fusion protein incorporating human serum albumin (HSA)-derived and human granulocyte colony stimulating factor (G-CSF)-derived moieties with potential granulopoietic…
A replication selective, recombinant, E1B and partial E3 gene deleted form of human adenovirus type 5, with potential antineoplastic activity. Upon intratumoral…
